Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Shares Issued (2016 - 2025)

Coherus Oncology's Shares Issued history spans 12 years, with the latest figure at $165000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 31.54% year-over-year to $165000.0; the TTM value through Dec 2025 reached $406000.0, down 56.16%, while the annual FY2025 figure was $353000.0, 61.88% down from the prior year.
  • Shares Issued for Q4 2025 was $165000.0 at Coherus Oncology, down from $241000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $4.3 million in Q1 2021 and bottomed at -$6.7 million in Q4 2021.
  • The 5-year median for Shares Issued is $392500.0 (2022), against an average of $513875.0.
  • The largest YoY upside for Shares Issued was 1363.11% in 2024 against a maximum downside of 5971.43% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$6.7 million in 2021, then skyrocketed by 109.89% to $665000.0 in 2022, then skyrocketed by 146.47% to $1.6 million in 2023, then tumbled by 85.3% to $241000.0 in 2024, then plummeted by 31.54% to $165000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Shares Issued are $165000.0 (Q4 2025), $241000.0 (Q4 2024), and -$822000.0 (Q2 2024).